EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019

Lukas Owens iD, Ojas Brahme, Roman Gulati iD, Ruth Etzioni iD

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Lukas Owens und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, SEER Program. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Rosalie and Harold Rea Brown Endowed Chair, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have shown that de novo metastatic prostate cancer incidence in the United States increased from 2010 to 2019. Plausible explanations include delayed detection after recommendations against prostate cancer screening or upstaging associated with use of more sensitive imaging technologies. Using Surveillance, Epidemiology, and End Results patient cases and controlling for aging of the population, we found the median age and prostate-specific antigen (PSA) level at prostate cancer diagnosis increased by 1.4 years of age (95% CI = 1.3 to 1.5 years) and 1.4 ng/mL (95% CI = 1.4 to 1.5 ng/mL) over this period, consistent with the delayed detection hypothesis. Racial differences were noted, with 75th percentiles of PSA at diagnosis increasing by 4.3 ng/mL (95% CI = 3.7 to 4.8 ng/mL) over this time period for non-Hispanic Black men compared with 3.0 ng/mL (95% CI = 2.8 to 3.2 ng/mL) for non-Hispanic White men. Overall, patient characteristics at diagnosis suggest that delayed detection contributed at least in part to increases in de novo metastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsSEER ProgramAgedAged, 80 and overHumansMaleMiddle AgedAge FactorsBlack or African AmericanDelayed DiagnosisEarly Detection of CancerIncidenceUnited StatesWhite

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.

ORCID-Profile: Lukas Owens, Roman Gulati, Ruth Etzioni

Förderung

  • NCI NIH HHS
  • Rosalie and Harold Rea Brown Endowed Chair
  • National Cancer Institute

Zitieren

APA

Owens, L., Brahme, O., Gulati, R., & Etzioni, R. (2024). Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae106

Vancouver

Owens L, Brahme O, Gulati R, Etzioni R. Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae106

BibTeX
@article{Owens2024,
  author = {Owens, Lukas and Brahme, Ojas and Gulati, Roman and Etzioni, Ruth},
  title = {Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae106}
}
Kostenlos starten →